Dahiroc, Rachel L.

HRN: 04-03-01  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/09/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
06/09/2025
06/16/2025
IV
250mg
Q24H
UTI
Waiting Final Action 

Indication:  Culture-directed    Type of Infection:  Urinary Tract    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: No  Wrong Dose  427.5 MG Q48 HOURS (PNF)

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: